Clinical significance of symptomatic and incidental venous thromboembolism in patients with cancer treated with apixaban.
- 1Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
- 2Department of Hematology, Akershus University Hospital, Lørenskog, Norway.
- 3Clinic of Internal Medicine, Østfold Hospital, Grålum, Norway.
Abstract
Background
Clinical characteristics and outcomes of patients with cancer with symptomatic vs incidental venous thromboembolism (VTE) remain poorly described.Methods
In this post hoc analysis of the apixaban as treatment of venous thrombosis in patients with cancer (CAP) study, we explored patients with cancer with VTE who received apixaban 5 mg twice daily for 6 months and then 2.5 mg twice daily for 30 months. Patients were classified as having symptomatic or incidental VTE at inclusion. The main outcomes were recurrent VTE and clinically relevant bleeding. Baseline characteristics and outcomes were compared between the 2 groups during a 36-month follow-up.Results
Of 284 patients, 163 (57%) had incidentally detected VTE. Compared with symptomatic patients, incidental patients had lower body mass index, more metastatic disease (79% vs 57%), and more pulmonary embolism or abdominal vein thrombosis. Deep vein thrombosis of the leg was more frequent in the symptomatic group (45.4% vs 7.4%, P < .001). There were more colorectal cancers in the incidental group (31.9% vs 19.0%, P = .01) and more hematological (14.1% vs 5.5%, P = .01) or breast cancers (14.9% vs 5.5%, P = .01) in the symptomatic group. Recurrent VTE occurred in 9.8% of incidental and 6.6% of symptomatic patients (subdistribution hazard ratio, 1.5; 95% CI, 0.6-3.5). Clinically relevant bleeding was more frequent in the incidental group (24.5% vs 13.2%; subdistribution hazard ratio, 1.9; 95% CI, 1.1-3.4). In the multivariable analysis, low hemoglobin and incidental VTE were independently associated with bleeding.Conclusion
The characteristics and outcomes in patients with incidental VTE differed from those with symptomatic VTE. While VTE recurrence was similar between the two groups, incidental VTE was associated with a higher risk of bleeding.
Related
- The 4D Repair Technique for Incidental Durotomy in Spine Surgery: Surgical Technique and Clinical Outcomes in 112 Patients
- Incidental Findings on Large-Field-of-View Cone Beam Computed Tomography Scans: Prevalence, Anatomical Distribution and Predictors of Clinical Relevance in a Retrospective Analysis of 203 Patients.
- Development and internal validation of a clinical prediction model for postoperative venous thromboembolism after neurosurgical intervention in patients with traumatic brain injury
- Integrating Genotype With Clinical Indicators Improves Venous Thromboembolism Risk Prediction in Cancer Patients: A Retrospective Cohort Study From Xinjiang
- Prognostic and Clinical Significance of Circulating Cystatin C Levels in Cancer Patients: A Meta-Analysis
BibTeX
@article{hussaini2026clinical,
title = {{Clinical significance of symptomatic and incidental venous thromboembolism in patients with cancer treated with apixaban.}},
author = {Parwana Hussaini and Trine-Lise Larsen and Waleed Ghanima and Anders Erik Astrup Dahm},
journal = {Research and practice in thrombosis and haemostasis},
year = {2026},
month = sep,
doi = {10.1016/j.rpth.2026.106968},
url = {https://europepmc.org/article/MED/42898096},
note = {CC BY},
}
RIS
TY - JOUR
TI - Clinical significance of symptomatic and incidental venous thromboembolism in patients with cancer treated with apixaban.
AU - Parwana Hussaini
AU - Trine-Lise Larsen
AU - Waleed Ghanima
AU - Anders Erik Astrup Dahm
PY - 2026
DA - 2026/09/14
JO - Research and practice in thrombosis and haemostasis
DO - 10.1016/j.rpth.2026.106968
UR - https://europepmc.org/article/MED/42898096
AB - Background Clinical characteristics and outcomes of patients with cancer with symptomatic vs incidental venous thromboembolism (VTE) remain poorly described.Methods In this post hoc analysis of the apixaban as treatment of venous thrombosis in patients with cancer (CAP) study, we explored patients with cancer with VTE who received apixaban 5 mg twice daily for 6 months and then 2.5 mg twice daily for 30 months. Patients were classified as having symptomatic or incidental VTE at inclusion. The main outcomes were recurrent VTE and clinically relevant bleeding. Baseline characteristics and outcomes were compared between the 2 groups during a 36-month follow-up.Results Of 284 patients, 163 (57%) had incidentally detected VTE. Compared with symptomatic patients, incidental patients had lower body mass index, more metastatic disease (79% vs 57%), and more pulmonary embolism or abdominal vein thrombosis. Deep vein thrombosis of the leg was more frequent in the symptomatic group (45.4% vs 7.4%, P < .001). There were more colorectal cancers in the incidental group (31.9% vs 19.0%, P = .01) and more hematological (14.1% vs 5.5%, P = .01) or breast cancers (14.9% vs 5.5%, P = .01) in the symptomatic group. Recurrent VTE occurred in 9.8% of incidental and 6.6% of symptomatic patients (subdistribution hazard ratio, 1.5; 95% CI, 0.6-3.5). Clinically relevant bleeding was more frequent in the incidental group (24.5% vs 13.2%; subdistribution hazard ratio, 1.9; 95% CI, 1.1-3.4). In the multivariable analysis, low hemoglobin and incidental VTE were independently associated with bleeding.Conclusion The characteristics and outcomes in patients with incidental VTE differed from those with symptomatic VTE. While VTE recurrence was similar between the two groups, incidental VTE was associated with a higher risk of bleeding.
SN - 2475-0379
ER -